Explore the complete details of the Asston Pharmaceuticals IPO, including issue size, price band, application process, risks, and financials. Make informed investment decisions today!
Overview of the Asston Pharmaceuticals IPO
The Asston Pharmaceuticals IPO is generating buzz among investors for good reason. Scheduled between July 9 to July 11, 2025, this issue offers shares in the price band of ₹115 to ₹123 per share with a lot size of 1,000 shares. To participate, investors must make a minimum investment of ₹2,30,000, equating to 2,000 shares.
This IPO aims to raise a total of ₹27.56 crore, positioning it as a mid-sized pharmaceutical sector offering in 2025.
Company Background and Key Operations
Founded in 2019 by Dr. Ashish Narayan Sakalkar, Asston Pharmaceuticals Ltd has carved a niche in the formulation and export of pharmaceutical and nutraceutical products. It manufactures tablets, syrups, powders, ointments, and injectables.
Notably, the company’s primary facility is in Ambernath, Maharashtra, adhering to strict FDA and FSSAI norms. It also holds WHO-GMP certification, ensuring global-quality compliance.
Moreover, the company has over 100 registered trademarks and supplies its products across Asian and African markets, showcasing impressive international reach.
Financial Performance Highlights
In recent years, Asston Pharmaceuticals has experienced strong financial momentum:
| Financial Year | Revenue | Profit After Tax (PAT) | Total Assets |
|---|---|---|---|
| FY 2023 | ₹6.54 Cr | ₹1.06 Cr | ₹14.14 Cr |
| FY 2024 | ₹15.59 Cr | ₹1.36 Cr | ₹25.04 Cr |
| FY 2025 (est.) | ₹25.04 Cr | ₹4.32 Cr | ₹40.00 Cr+ (est.) |
Clearly, the company’s bottom line is trending upwards, offering a promising return potential.
Also Read: Amazon affiliate program
Detailed IPO Application Process
Investors can apply under two categories:
- Regular Investors: Apply up to ₹2,00,000
- High Net Worth Individuals (HNIs): Apply between ₹2,00,000 and ₹5,00,000
The issue size is 27.56 crore with strong institutional subscription interest, signaling market confidence.
Shareholding and Institutional Interest
Subscription figures as of July 11, 12 PM:
- Qualified Institutional Buyers (QIBs): 7.98x
- Non-Institutional Investors (NIIs): 52.25x
- Retail Individual Investors (RIIs): 38.29x
- Total Subscription: 21.77x
These figures suggest overwhelming investor demand and indicate robust listing potential.
Strengths of Asston Pharmaceuticals Ltd
- In-House R&D and Formulation
The company boasts advanced formulation capabilities across diverse drug types. - Regulatory Certifications
Certified by the FDA (India & US), WHO-GMP, FSSAI, and Nuclear Quality Assurance (NQA). - Export-Focused Business
80.21% of revenue is export-driven, primarily to Sierra Leone and other emerging markets. - Strong Client & Vendor Network
Strategic partnerships and a wide supplier base enhance operational flexibility.
- Industry Leading noise cancellation-two processors control 8 microphones for unprecedented noise cancellation. With Auto…
- Industry-leading call quality with our Precise Voice Pickup Technology uses four beamforming microphones and an AI-based…
- Magnificent Sound, engineered to perfection with the new Integrated Processor V1
Key Business Risks for Investors
Despite its strengths, the IPO carries several risks:
- Overdependence on Select Clients
Top 5 customers contribute over 71.18% of revenue. - Limited Product Diversification
Revenue concentration in a few products may affect long-term scalability. - High Financial Leverage
The company has an outstanding financial liability of ₹7.83 crore, which might impact liquidity. - Third-party Reliance
Heavy dependency on outsourced manufacturing and raw materials could disrupt supply.
SWOT Analysis of Asston Pharmaceuticals IPO
| Strengths | Weaknesses |
|---|---|
| – WHO-GMP certified | – High client dependency |
| – Rising revenues | – Supplier reliance |
| – Global market access | – Narrow product focus |
| Opportunities | Threats |
|---|---|
| – Expanding into new regions | – Global regulatory risks |
| – New formulations & IPs | – Forex volatility & competition |
Comparison with Recent Pharma IPOs
Compared to other recent pharmaceutical IPOs in India, Asston Pharmaceuticals stands out for its lean structure, early profitability, and diversified geographic revenue. However, it is more exposed to external market fluctuations than some larger peers.
Frequently Asked Questions (FAQs)
Q1. What is the issue size of Asston Pharmaceuticals Ltd IPO?
A1. The issue size is ₹27.56 crore.
Q2. What is the IPO price band and lot size?
A2. Price is ₹115–₹123. Lot size is 1,000 shares.
Q3. What is the minimum investment required?
A3. ₹2,30,000 for 2,000 shares.
Q4. When is the bidding window open?
A4. From July 9 to July 11, 2025.
Q5. What is the registrar of this IPO?
A5. The registrar is not specified in the image.
Q6. Where will the IPO be listed?
A6. The listing exchange isn’t specified but will likely be NSE/BSE.
Final Verdict on the Asston Pharmaceuticals IPO
The Asston Pharmaceuticals IPO, investors should weigh the associated risks and only invest based on personal financial goals.
**Disclaimer: However, always review your risk appetite and portfolio mix before committing.**
**Disclaimer: The Image in the article is taken from google is used for article which is generated by Chatgpt content. always review your risk appetite and portfolio mix before committing. We are not Finanacial advisors this content is our own analysis and any loss or gains are not subjected to our mention opinon. Invest at your own risk**
Join Us on Social Media!
Stay updated with the latest from EasyBuzz. Connect with us: